Sign inJoin waitlistJoin the waitlist

Shreyas Joshi

Program Director, Urologic Oncology Fellowship · Emory University School of Medicine

Credentials: · · · · · ·

History

Urologic Oncology Fellowship · Emory University School of Medicine
Present
Emory University School of Medicine
Present
Ambulatory Urology Operations for Emory University Hospital · Emory University School of Medicine
Present

Fox Chase Cancer Center
2018–2019
Temple University Hospital
Fox Chase Cancer Center
2016–2018
Urology
Vanderbilt University Medical Center
2012–2016
General Surgery
Vanderbilt University Medical Center
2011–2012
Temple University College of Public Health
Indiana University School of Medicine
2007–2011

Research

Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies
Review · Molecular Cancer Therapeutics · 2018 · 410 citations
CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor
Immunity · 2023 · 307 citations
18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase…
The Lancet · 2021 · 160 citations

Viraj Master
45 papers
Vikram Narayan
36 papers · 10 as a fellow
Kenneth Ogan
35 papers
Mehmet Bilen
30 papers
Reza Nabavizadeh
21 papers · 10 as a resident
Bradley Carthon
17 papers
Omer Kucuk
16 papers
Robert Uzzo
16 papers
Alexander Kutikov
15 papers
Mohammad Hajiha
15 papers
Reza Lahiji
14 papers · 13 as a resident
Ashesh Jani
13 papers

Clinical trials

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG
Site PI · Recruiting · Phase 1, Phase 2
ImmunityBio, Inc.
2025–2028
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Site PI · Recruiting · Phase 2
CG Oncology, Inc.
2024–2027
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Site PI · Recruiting · Phase 3
SWOG Cancer Research Network
2018–2031
ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer
Site PI · Available
ImmunityBio, Inc.